Please login to the form below

basal cell carcinoma

This page shows the latest basal cell carcinoma news and features for those working in and with pharma, biotech and healthcare.

Pfizer gets first FDA nod for hedgehog inhibitor in AML

The small-molecule drug blocks part of the Sonic hedgehog pathway, which is also targeted by other cancer drugs including Roche’s Erivedge (vismodegib) and Novartis’ Odomzo (sonidegib) for basal cell ... metastatic non-small cell lung cancer (NSCLC),

Latest news

Sanofi’s latecomer PD-1 gets date for FDA verdict

The US regulator has given a priority review for PD-1-targeting cemiplimab because its first indication – cutaneous squamous cell carcinoma (CSCC) – is the second most common form of skin cancer ... after basal cell carcinoma (BCC) and the deadliest
Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

The data in cutaneous squamous cell carcinoma (CSCC), the second most common form of skin cancer, comes from a single-arm, open-label trial involving 82 patients and showed an overall ... The company plans to have pivotal trials ongoing in first-line
Pfizer's SMO inhibitor boosts survival in blood cancer trial

basal cell carcinoma in patients not suitable for surgery or radiotherapy. ... in a phase I/II trial in small cell lung cancer (SCLC) patients.
Rare disease therapies head the ‘class of 2015’

A product in a new class of cancer therapies that harness the cell-killing power of viruses also debuted in 2015 in the form of Amgen's Imlygic (talimogene laherparepvec), the ... Actelion. USA. sonidegib. Odomzo. basal cell carcinoma. SMO receptor
EU green light for Novartis' skin cancer therapy

Swiss firm’s basal cell carcinoma treatment can now be launched across Europe. . ... Odomzo (sonidegib) is used to treat locally-advanced basal cell carcinoma - the most common form of skin cancer - in patients for whom surgery or radiation therapy

More from news
Approximately 5 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch December 2016

295. Novartis (Switzerland). Sun Pharma (India). Asset acquisition. Odomzo (sonidegib; hedgehog pathway inhibitor), approved in basal cell carcinoma. ... Abzena's technology is used to humanise and de-immunise antibodies by avoiding CD4+ T-cell epitopes.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

Chris Bowden joins Agios

During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
Curis looks to MedImmune and Takeda for new hires

Curis also worked with Roche to Erivedge (vismodegib), which recently won approval for the treatment of advanced basal cell carcinoma (BCC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Editorial Manager - MedComms: DOE

Healthcare Communications Account Directors x 2: Salary TBC

Digital Communications Lead, Healthcare Brand and Medical Commun...: up to £50K

Account Director: Competitive Salary Offered

Chief Medical Writer, Medical Communications, London, up to £90K...: up to £90K

Senior Account Manager: Competitive Salary Offered

Account Manager / Account Director: Competative

Systematic Reviewer - Oxford: Negotiable

SAE – Healthcare PR – Award-Winning Consultancy: Salary TBC

Engagement Specialist, Healthcare Brand Communications, London, ...: circa £50K

Account Director – Healthcare Marketing – Berks: Salary TBC

Account Manager / Senior Account Manager: 35, 000-40, 000

Medical Writer: Salary TBC

Account Manager: Negotiable

Senior Account Executive with progression to Account Manager, Me...: Excellent package

Principal Health Economist - North-West: Negotiable

Medical (Scientific) Director: £120, 000 benefits

Experienced Medical Writers: Competitive Salary and Benefits

CALLING ALL SENIOR HEALTHCARE PR FREELANCERS!!!!! ACCOUNT DIRECT...: EXCELLENT DAY RATES AVAILABLE

Associate Medical Director: Excellent PTO, bonus and 401k package

Senior Developer with management potential, Healthcare Brand Com...: circa £50K

Senior Editorial Assistant – Greater Manchester: DOE

Business Development Director – Health Education: excellent commission

Account Executive/ Senior Account Executive: competitive Salary Offfered

Medical Writer: Bonus Scheme, PTO &Private Healthcare

Subscribe to our email news alerts

PMHub

Add my company

Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

AstraZeneca’s oncology renaissance: Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis: Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls: ‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...